{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:29:21Z","timestamp":1790958561681,"version":"4.1.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Mesothelin (MSLN) is a glycoprotein with various expression degrees in different tumors including mesothelioma, ovarian cancer, pancreatic cancer, etc. MSLN is considered to play an important role in cell survival, proliferation, and tumor progression. Although the expression of MSLN in tumors makes it a potential therapeutic target, its mechanism of action is still unclear, especially its correlation with immune cells infiltration in the tumor microenvironment has not been investigated. In this study, we detected the overexpression of MSLN in ovarian cancer using database analysis and tissue-array staining. We further evaluated the diagnostic value of MSLN and found it was associated with poor overall survival in ovarian cancer. In addition, the high expression of MSLN was significantly related to the immune-related genes and chemoresistant genes. We confirmed the overexpression of MSLN in the chemoresistant ovarian cancer cell lines. Our research suggests that MSLN participates in a variety of pathways related to the suppression of immune activation and promotion of chemoresistance, leading to a poor prognosis in ovarian cancer.<\/jats:p>","DOI":"10.3389\/fonc.2022.830570","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T05:49:33Z","timestamp":1653457773000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["MSLN Correlates With Immune Infiltration and Chemoresistance as a Prognostic Biomarker in Ovarian Cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"Yike","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjia","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghe","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningjing","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer Statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejcsup.2019.11.001","article-title":"Insight Updating of the Molecular Hallmarks in Ovarian Carcinoma","volume":"15","author":"Mota","year":"2020","journal-title":"EJC Suppl"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2018.06.036","article-title":"Origins Based Clinical and Molecular Complexities of Epithelial Ovarian Cancer","volume":"118","author":"Muinao","year":"2018","journal-title":"Int J Biol Macromol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3892\/ijo.2021.5233","article-title":"A Multidisciplinary Approach Remains the Best Strategy to Improve and Strengthen the Management of Ovarian Cancer (Review)","volume":"59","author":"Falzone","year":"2021","journal-title":"Int J Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"viii13","DOI":"10.1093\/annonc\/mdx446","article-title":"Acquired Chemotherapy Resistance in Ovarian Cancer","volume":"28","author":"Christie","year":"2017","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of Mesothelin Immunostaining in Tumor Diagnosis","volume":"27","author":"Ord\u00f3\u00f1ez","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin is Not Required for Normal Mouse Development or Reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol Cell Biol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.39012","article-title":"Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)","volume":"17","author":"Le","year":"2020","journal-title":"Int J Med Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40364-019-0169-8","article-title":"Mesothelin as a Biomarker for Targeted Therapy","volume":"7","author":"Lv","year":"2019","journal-title":"Biomark Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3390\/biom10070973","article-title":"Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors","volume":"10","author":"Hagerty","year":"2020","journal-title":"Biomolecules"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6671","article-title":"Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis","volume":"30","author":"Hollevoet","year":"2012","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-19-0688","article-title":"Mesothelin Enhances Tumor Vascularity in Newly Forming Pancreatic Peritoneal Metastases","volume":"18","author":"Avula","year":"2020","journal-title":"Mol Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2006.03.029","article-title":"Development of a CA125-Mesothelin Cell Adhesion Assay as a Screening Tool for Biologics Discovery","volume":"247","author":"Scholler","year":"2007","journal-title":"Cancer Lett"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11290","article-title":"Diffuse Mesothelin Expression Leads to Worse Prognosis Through Enhanced Cellular Proliferation in Colorectal Cancer","volume":"19","author":"Inoue","year":"2020","journal-title":"Oncol Lett"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2018.1418326","article-title":"Peritoneal Dissemination of Ovarian Cancer: Role of MUC16-Mesothelin Interaction and Implications for Treatment","volume":"18","author":"Coelho","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody With Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"TPS8576","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS8576","article-title":"A Pivotal Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients With Advanced or Metastatic Pleural Mesothelioma After Progression on Platinum\/Pemetrexed-Based Chemotherapy (NCT02610140)","volume":"34","author":"Hassan","year":"2016","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin Immunotherapy for Cancer: Ready for Prime Time","volume":"34","author":"Hassan","year":"2016","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1476-4598-10-106","article-title":"Mesothelin Confers Pancreatic Cancer Cell Resistance to TNF-\u03b1-Induced Apoptosis Through Akt\/PI3K\/NF-\u03bab Activation and IL-6\/Mcl-1 Overexpression","volume":"10","author":"Bharadwaj","year":"2011","journal-title":"Mol Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1397","article-title":"Diffuse Mesothelin Expression Correlates With Prolonged Patient Survival in Ovarian Serous Carcinoma","volume":"12","author":"Yen","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41389-020-00246-2","article-title":"Regulation of Invasion and Peritoneal Dissemination of Ovarian Cancer by Mesothelin Manipulation","volume":"9","author":"Coelho","year":"2020","journal-title":"Oncogenesis"},{"key":"B22","article-title":"High Expression of Mesothelin in Advanced Serous Ovarian Cancer Is Associated With Poor Prognosis","volume":"24","author":"Yildiz","year":"2019","journal-title":"J Buon"},{"key":"B23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41419-022-04510-8","article-title":"Extracellular Vesicles in Ovarian Cancer Chemoresistance, Metastasis, and Immune Evasion","volume":"13","author":"Tian","year":"2022","journal-title":"Cell Death Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3772","article-title":"Toil Enables Reproducible, Open Source, Big Biomedical Data Analyses","volume":"35","author":"Vivian","year":"2017","journal-title":"Nat Biotechnol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btm254","article-title":"GEOquery: A Bridge Between the Gene Expression Omnibus (GEO) and BioConductor","volume":"23","author":"Davis","year":"2007","journal-title":"Bioinformatics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex Heatmaps Reveal Patterns and Correlations in Multidimensional Genomic Data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.10.003","article-title":"Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer","volume":"39","author":"Bindea","year":"2013","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-1370","article-title":"CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set","volume":"72","author":"Reinhold","year":"2012","journal-title":"Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): A Resource for Therapeutic Biomarker Discovery in Cancer Cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12935-020-1139-9","article-title":"Long Non-Coding RNA DANCR Promotes Cervical Cancer Growth via Activation of the Wnt\/\u03b2-Catenin Signaling Pathway","volume":"20","author":"Tian","year":"2020","journal-title":"Cancer Cell Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201811_16268","article-title":"CD151 Promotes Breast Cancer Metastasis by Activating TGF-\u03b21\/Smad Signaling Pathway","volume":"22","author":"Zhao","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1042\/BST20160478","article-title":"CD81 as a Tumor Target","volume":"45","author":"Vences-Catal\u00e1n","year":"2017","journal-title":"Biochem Soc Trans"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.6704","article-title":"RecQ Helicase BLM Regulates Prostate Cancer Cell Proliferation and Apoptosis","volume":"14","author":"Qian","year":"2017","journal-title":"Oncol Lett"},{"key":"B34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.exer.2018.08.022","article-title":"BLM can Regulate Cataract Progression by Influencing Cell Vitality and Apoptosis","volume":"178","author":"Xiang","year":"2019","journal-title":"Exp Eye Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","article-title":"Conserved Interferon-\u03b3 Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma","volume":"38","author":"Grasso","year":"2020","journal-title":"Cancer Cell"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nature24293","article-title":"IL-1R8 is a Checkpoint in NK Cells Regulating Anti-Tumour and Anti-Viral Activity","volume":"551","author":"Molgora","year":"2017","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s12026-021-09211-6","article-title":"Recent Advances in the Role of Th17\/Treg Cells in Tumor Immunity and Tumor Therapy","volume":"69","author":"Qianmei","year":"2021","journal-title":"Immunol Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.imlet.2014.11.013","article-title":"Human Megakaryocyte Progenitors Derived From Hematopoietic Stem Cells of Normal Individuals are MHC Class II-Expressing Professional APC That Enhance Th17 and Th1\/Th17 Responses","volume":"163","author":"Finkielsztein","year":"2015","journal-title":"Immunol Lett"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0710686105","article-title":"Generation and Regulation of Human CD4+ IL-17-Producing T Cells in Ovarian Cancer","volume":"105","author":"Miyahara","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.3390\/cancers13163932","article-title":"Hitting the Bull's-Eye: Mesothelin's Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma","volume":"13","author":"Yeo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40364-021-00264-1","article-title":"Anti-Mesothelin CAR T Cell Therapy for Malignant Mesothelioma","volume":"9","author":"Castelletti","year":"2021","journal-title":"Biomark Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1758835920917571","DOI":"10.1177\/1758835920917571","article-title":"Mesothelin Expression in Esophageal Adenocarcinoma and Squamous Cell Carcinoma and its Possible Impact on Future Treatment Strategies","volume":"12","author":"Moentenich","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-018-0567-0","article-title":"The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review","volume":"13","author":"Nichetti","year":"2018","journal-title":"Target Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604964","article-title":"High Mesothelin Correlates With Chemoresistance and Poor Survival in Epithelial Ovarian Carcinoma","volume":"100","author":"Cheng","year":"2009","journal-title":"Br J Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01300","article-title":"Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium","volume":"9","author":"Falzone","year":"2018","journal-title":"Front Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.3390\/cancers12123733","article-title":"Immunotherapy Advances for Epithelial Ovarian Cancer","volume":"12","author":"Hartnett","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3390\/cancers11101472","article-title":"Current Perspectives in Cancer Immunotherapy","volume":"11","author":"Christofi","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S205950","article-title":"Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches","volume":"13","author":"Palaia","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and Paclitaxel-Carboplatin Chemotherapy and Secondary Cytoreduction in Recurrent, Platinum-Sensitive Ovarian Cancer (NRG Oncology\/Gynecologic Oncology Group Study GOG-0213): A Multicentre, Open-Label, Randomised, Phase 3 Trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.12.001","article-title":"Activity of Bevacizumab (rhuMAB VEGF) in Advanced Refractory Epithelial Ovarian Cancer","volume":"96","author":"Monk","year":"2005","journal-title":"Gynecol Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cyto.2015.09.011","article-title":"Interleukin-17 Acts as Double-Edged Sword in Anti-Tumor Immunity and Tumorigenesis","volume":"89","author":"Qian","year":"2017","journal-title":"Cytokine"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085935","article-title":"MSLN Gene Silencing has an Anti-Malignant Effect on Cell Lines Overexpressing Mesothelin Deriving From Malignant Pleural Mesothelioma","volume":"9","author":"Melaiu","year":"2014","journal-title":"PloS One"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111441","article-title":"PARP-1-Associated Pathological Processes: Inhibition by Natural Polyphenols","volume":"22","author":"Maluchenko","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.223701","article-title":"Synergistic Effect of a Mesothelin-Targeted (227)Th Conjugate in Combination With DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models","volume":"60","author":"Wickstroem","year":"2019","journal-title":"J Nucl Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.830570\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T05:49:43Z","timestamp":1653457783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.830570\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":54,"alternative-id":["10.3389\/fonc.2022.830570"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.830570","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,25]]},"article-number":"830570"}}